<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PSA Rising Prostate Cancer Blog &#187; Provenge</title>
	<atom:link href="http://www.psa-rising.com/blog/category/pca/pca-tx/vax/provenge/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.psa-rising.com/blog</link>
	<description></description>
	<lastBuildDate>Thu, 12 Nov 2009 17:35:32 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Dendreon to seek Provenge approval in November &#8211; Reuters</title>
		<link>http://www.psa-rising.com/blog/2009/09/dendreon-to-seek-provenge-approval-in-november-reuters/</link>
		<comments>http://www.psa-rising.com/blog/2009/09/dendreon-to-seek-provenge-approval-in-november-reuters/#comments</comments>
		<pubDate>Thu, 24 Sep 2009 14:57:22 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[FDA]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=2017</guid>
		<description><![CDATA[Reuters and WAll Street Journal report today that Dendreon plans to seek US FDA approval for Provenge prostate cancer vaccine in November. Dendreon  &#8220;expects regulators to act on the application by the middle of next year, the company said on Thursday.&#8221;
To start from an updated report in the Wall Street Journal, which adds this [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/09/dendreon-to-seek-provenge-approval-in-november-reuters/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reactions to Provenge Data</title>
		<link>http://www.psa-rising.com/blog/2009/04/reactions-to-provenge-data/</link>
		<comments>http://www.psa-rising.com/blog/2009/04/reactions-to-provenge-data/#comments</comments>
		<pubDate>Tue, 28 Apr 2009 20:50:30 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[Immunotherapy]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=1264</guid>
		<description><![CDATA[“These results confirm the clinical value of Provenge to prolong survival in patients with advanced prostate cancer,” said Dr. Philip Kantoff, head of the prostate cancer program and chief of the division of solid tumor oncology at the Dana-Farber Cancer Institute and Harvard Medical School, and a principal investigator of the Provenge study, in a [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/04/reactions-to-provenge-data/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men with Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study</title>
		<link>http://www.psa-rising.com/blog/2009/04/data-presented-at-aua-demonstrate-provenge-significantly-prolongs-survival-for-men-with-advanced-prostate-cancer-in-pivotal-phase-3-impact-study/</link>
		<comments>http://www.psa-rising.com/blog/2009/04/data-presented-at-aua-demonstrate-provenge-significantly-prolongs-survival-for-men-with-advanced-prostate-cancer-in-pivotal-phase-3-impact-study/#comments</comments>
		<pubDate>Tue, 28 Apr 2009 18:13:39 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=1262</guid>
		<description><![CDATA[– Extended Median Survival by 4.1 Months and Increased 3-Year Survival by 38 Percent Compared to Placebo –
– First Active Cellular Immunotherapy for Cancer to Prolong Survival –
– Company to Host Webcast at 5:30 pm ET – 
CHICAGO and SEATTLE, April 28, 2009 &#8211; Dendreon Corporation (NASDAQ: DNDN) today announced that its pivotal Phase 3 [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/04/data-presented-at-aua-demonstrate-provenge-significantly-prolongs-survival-for-men-with-advanced-prostate-cancer-in-pivotal-phase-3-impact-study/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Investor Interviews Hy Levitsky M.D. on Provenge</title>
		<link>http://www.psa-rising.com/blog/2009/04/investorv-interview-with-hy-levitsky/</link>
		<comments>http://www.psa-rising.com/blog/2009/04/investorv-interview-with-hy-levitsky/#comments</comments>
		<pubDate>Thu, 23 Apr 2009 03:50:15 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Biotech companies]]></category>
		<category><![CDATA[Cancer Treatments]]></category>
		<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[Immunotherapy]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[trial results]]></category>
		<category><![CDATA[Add new tag]]></category>
		<category><![CDATA[Dendreon IV board]]></category>
		<category><![CDATA[HY Levitsky M.D.]]></category>
		<category><![CDATA[rufustoehee]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=1177</guid>
		<description><![CDATA[A four part interview with  Hy Levitsky M.D., professor of oncology and tumor immunology at Johns Hopkins Medical School and co-inventor GVAX anti-cancer vaccine, is posted on Dendreon Investor Village website.
Interview conducted by rufustoehee, a dentist and Dendreon investor, published 4/22/2009.

By way of introduction, Dr Levitsky&#8217;s bio is posted alphabetically downpage among those of other [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/04/investorv-interview-with-hy-levitsky/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dendreon Director Sells Stock Options on Day Provenge &#8220;Success&#8221; Touted</title>
		<link>http://www.psa-rising.com/blog/2009/04/dendreon-director-sells-options/</link>
		<comments>http://www.psa-rising.com/blog/2009/04/dendreon-director-sells-options/#comments</comments>
		<pubDate>Thu, 16 Apr 2009 18:51:59 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=973</guid>
		<description><![CDATA[A Dendreon Inc., director, Gerardo Canet, sold over 200,000 stock options in the company on April 14 “pursuant to a Rule 10b5-1 trading plan.” Such trading plans are set up to defend company insiders from allegations of trading on insider information.]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/04/dendreon-director-sells-options/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Provenge Significantly Extends Survival of Men With Advanced Prostate Cancer, Dendreon Says</title>
		<link>http://www.psa-rising.com/blog/2009/04/951/</link>
		<comments>http://www.psa-rising.com/blog/2009/04/951/#comments</comments>
		<pubDate>Tue, 14 Apr 2009 15:15:45 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer Treatments]]></category>
		<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=951</guid>
		<description><![CDATA[Dendreon&#8217;s prostate cancer vaccine significantly prolonged the overall survival among 500 men with advanced, metastic  prostate cancer  compared to a placebo, the company said Tuesday.
Results were &#8220;robust&#8221; and &#8220;unambiguous,&#8221; a spokesman said during today&#8217;s (Tues April 14) company broadcast conference call with biotech investment analysts.
&#8220;The successful outcome from the Phase 3 IMPACT study provides validation [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/04/951/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Provenge and Meta-Analysis &#8212; Compare Avandia</title>
		<link>http://www.psa-rising.com/blog/2007/07/provenge-and-meta-analysis-compare-avandia/</link>
		<comments>http://www.psa-rising.com/blog/2007/07/provenge-and-meta-analysis-compare-avandia/#comments</comments>
		<pubDate>Sun, 08 Jul 2007 02:08:09 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Chemotherapy]]></category>
		<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Avandia]]></category>
		<category><![CDATA[clinical trials]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/?p=330</guid>
		<description><![CDATA[In submitting Provenge vaccine for the treatment of advanced prostate cancer for fast-tracked FDA approval despite aborting one clinical trial due to failure to meet the primary endpoint, Dendreon relied on meta-analysis of combined data from two parts of a phase III study, D9901. In fact, after the trials failed to meet their primary endpoint, [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/07/provenge-and-meta-analysis-compare-avandia/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Video of FDA hearing on Provenge March 29th</title>
		<link>http://www.psa-rising.com/blog/2007/06/video-of-fda-hearing-on-provenge-march-29th/</link>
		<comments>http://www.psa-rising.com/blog/2007/06/video-of-fda-hearing-on-provenge-march-29th/#comments</comments>
		<pubDate>Thu, 07 Jun 2007 14:08:29 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[video]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/06/07/video-of-fda-hearing-on-provenge-march-29th</guid>
		<description><![CDATA[A link to a 5 hour video recording of the FDA Advisory Committee hearing held March 29 on sipuleucel-T (Provenge) for advanced, androgen independent prostate cancer. The video does not include the vote.
A full written transcript in .pdf including the voting is online at FDA, click here. 
]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/06/video-of-fda-hearing-on-provenge-march-29th/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prostate cancer patients, families, rally in Washington D.C.</title>
		<link>http://www.psa-rising.com/blog/2007/06/prostate-cancer-patients-families-rally-in-washington-dc/</link>
		<comments>http://www.psa-rising.com/blog/2007/06/prostate-cancer-patients-families-rally-in-washington-dc/#comments</comments>
		<pubDate>Wed, 06 Jun 2007 04:45:51 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Activism]]></category>
		<category><![CDATA[FDA]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/06/05/prostate-cancer-patients-families-rally-in-washington-dc</guid>
		<description><![CDATA[
A crowd of about 70 people led by prostate cancer advocates marched and rallied in  Washington, D.C. on June 4 to call on the FDA to Approve  Provenge Now.  

Thomas Farrington of Prostate Health Education Network addressed the group.

Raise a Voice  organizer Jan Manarite  introduced speakers including Tom  Farrington [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/06/prostate-cancer-patients-families-rally-in-washington-dc/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prostate Cancer Doctor Receives Death Threat Over Provenge</title>
		<link>http://www.psa-rising.com/blog/2007/06/prostate-cancer-doctor-receives-death-threat-over-provenge/</link>
		<comments>http://www.psa-rising.com/blog/2007/06/prostate-cancer-doctor-receives-death-threat-over-provenge/#comments</comments>
		<pubDate>Mon, 04 Jun 2007 04:25:39 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[FDA]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/06/03/prostate-cancer-doctor-receives-death-threat-over-provenge</guid>
		<description><![CDATA[Oncologist Dr. Howard I. Scher has received a death threat for opposing immediate FDA approval of Dendreon&#8217;s Provenge therapeutic vaccine for prostate cancer.  Another oncologist who opposes approval of Provenge without completion of an ongoing clinical trial, Dr. Maha Hussain, has received unspecified threats.

The background to these threats goes back to March 29, when [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/06/prostate-cancer-doctor-receives-death-threat-over-provenge/feed/</wfw:commentRss>
		<slash:comments>4</slash:comments>
		</item>
	</channel>
</rss>
